Assessment of heterogeneity among participants in the Parkinson's Progression Markers Initiative cohort using α-synuclein seed amplification: a cross-sectional study-Reference-Cited by-同舟云学术

Assessment of heterogeneity among participants in the Parkinson's Progression Markers Initiative cohort using α-synuclein seed amplification: a cross-sectional study

Published:2023-05 Issue:5 Volume:22 Page:407-417
ISSN:1474-4422
Container-title:The Lancet Neurology
language:en
Short-container-title:The Lancet Neurology

Author:

Siderowf Andrew,Concha-Marambio Luis,Lafontant David-Erick,Farris Carly M,Ma Yihua,Urenia Paula A,Nguyen Hieu,Alcalay Roy N,Chahine Lana M,Foroud Tatiana,Galasko Douglas,Kieburtz Karl,Merchant Kalpana,Mollenhauer Brit,Poston Kathleen L,Seibyl John,Simuni Tanya,Tanner Caroline M,Weintraub Daniel,Videnovic Aleksandar,Choi Seung Ho,Kurth Ryan,Caspell-Garcia Chelsea,Coffey Christopher S,Frasier Mark,Oliveira Luis M A,Hutten Samantha J,Sherer Todd,Marek Kenneth,Soto Claudio

Publisher

Elsevier BV

Subject

Neurology (clinical)

Reference35 articles.

1. CSF and blood biomarkers for Parkinson's disease;Parnetti;Lancet Neurol,2019

2. Staging of brain pathology related to sporadic Parkinson's disease;Braak;Neurobiol Aging,2003

3. Alpha-synuclein in Lewy bodies;Spillantini;Nature,1997

4. Multi-organ distribution of phosphorylated alpha-synuclein histopathology in subjects with Lewy body disorders;Beach;Acta Neuropathol,2010

5. Skin nerve α-synuclein deposits: a biomarker for idiopathic Parkinson disease;Donadio;Neurology,2014

Cited by 238 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Alpha-synuclein fine-tunes neuronal response to pro-inflammatory cytokines;Brain, Behavior, and Immunity;2024-11

2. Lewy body pathology exacerbates brain hypometabolism and cognitive decline in Alzheimer’s disease;Nature Communications;2024-09-14

3. Research advancement in fluid biomarkers for Parkinson’s disease;Expert Review of Molecular Diagnostics;2024-09-11

4. International Parkinson and Movement Disorder Society Viewpoint on Biological Frameworks of Parkinson's Disease: Current Status and Future Directions;Movement Disorders;2024-09-09

5. Investigating the Mechanisms of Antibody Binding to Alpha-Synuclein for the Treatment of Parkinson’s Disease;Molecular Pharmaceutics;2024-09-09